PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25048018-0	2014	Inhibition of smooth muscle cell proliferation by ezetimibe via the cyclin D1-MAPK pathway.	Ezetimibe	50-59	cyclin D1	Rattus norvegicus	68-77	
25048018-5	2014	Mechanically, we found that ezetimibe was capable of abolishing cyclin D1, CDK2, phospho-Rb (p-Rb), and E2F protein expressions that were upregulated by Chol:MbetaCD treatment.	Ezetimibe	28-37	cyclin D1	Rattus norvegicus	64-73	
25048018-6	2014	In addition, Ezetimibe was able to reverse cell cycle progression induced by Chol:MbetaCD, which was further supported by its down-regulation of cyclin D1 promoter activity in the presence of Chol:MbetaCD.	Ezetimibe	13-22	cyclin D1	Rattus norvegicus	145-154	
25048018-8	2014	Inhibition of the MAPK pathway by using ERK1/2 inhibitor PD98059 attenuated the reduction effect of ezetimibe on the expressions of phosphor-MEK1 (p-MEK1), p-ERK1/2, and cyclin D1.	Ezetimibe	100-109	cyclin D1	Rattus norvegicus	170-179	
25048018-9	2014	Taken together our data suggest that ezetimibe inhibits Chol:MbetaCD-induced VSMCs proliferation and leads to cell cycle arrest at the G0/G1 phase by suppressing cyclin D1 expression via the MAPK signaling pathway.	Ezetimibe	37-46	cyclin D1	Rattus norvegicus	162-171